Tiziana Sets Nov 9 KOL Call, Quantifies INFORM-MS Wins (p=0.0168)
TLSA is trading near its 52-week low of $0.567 (10% above the low).
Summary
Tiziana scheduled a November 9 KOL call and put hard numbers on its INFORM-MS win: p=0.0168 on the 50μg TSPO PET endpoint and significant fatigue improvements in both dose arms. The data support a pivotal trial, which the company must now fund against a thin cash position.
Key Events · Product Development and Regulatory · TLSA
-
KOL Call Set for November 9
Management will host a webcast at 12:00pm ET / 17:00pm GMT with Drs. Tanuja Chitnis, Tarun Singhal and Howard Weiner to review the INFORM-MS dual primary endpoint results and secondary findings.
-
Primary Endpoint p=0.0168 at 50μg
The 50μg nasal foralumab arm showed a statistically significant reduction in microglial activation on [18F]PBR06 TSPO PET versus placebo; the 100μg arm was exploratory and showed variance in PET outcomes.
-
Fatigue Scores Improve in Both Arms
MFIS total score fell 6.17 points in the 50μg arm (p=0.035) and 7.18 points in the 100μg arm (p=0.040) after 12 weeks, versus a 3.12-point drop on placebo.
-
Clean Safety Across 48 Patients
All 48 participants completed treatment with no study-drug related serious adverse events, supporting the non-invasive anti-CD3 profile.
Analysis · TLSA · Life Sciences
This filing adds detail to the 2026-11-02 topline release: the 50μg arm's TSPO PET reduction reached p=0.0168, and fatigue scores fell 6.17 points (p=0.035) and 7.18 points (p=0.040) in the two dose arms versus 3.12 points on placebo. All 48 patients completed with no drug-related serious adverse events. The numbers matter because they are the package Tiziana will take to the FDA for a pivotal trial design, and because the company reported only $3.9M of cash with going-concern doubt on 2026-10-16 — positive, well-quantified data is the main lever for financing that pivotal program. The November 9 call is where investigators explain the dose-response variance between 50μg and 100μg.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TLSA was trading at $0.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $80.2M. The 52-week trading range was $0.57 to $1.90. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.